Anticancer copper complex with nucleus, mitochondrion and cyclooxygenase-2 as multiple targets

Area of Science:

• Medicinal Chemistry
• Nanotechnology
• Biochemistry

Background:

• Copper complexes exhibit promising anticancer properties and biocompatibility.
• Inflammation significantly impacts tumor progression and therapeutic responses.
• Targeting both cancer cells and inflammation is crucial for effective treatment.

Purpose of the Study:

• To synthesize and evaluate a novel copper(II) complex, CuLA, with potential dual anticancer and anti-inflammatory activities.
• To investigate the mechanism of action of CuLA on cancer cells and inflammatory pathways.
• To assess the role of aspirin ligands in enhancing the therapeutic efficacy of copper complexes.

Main Methods:

• Synthesis of copper(II) complex CuLA and its analogue CuL.
• Evaluation of cytotoxic activity and apoptosis induction in SKOV-3 cancer cells.
• Assessment of mitochondrial dysfunction and cellular redox homeostasis.
• Analysis of cyclooxygenase-2 (COX-2) expression in lipopolysaccharide-stimulated RAW 264.7 cells.

Main Results:

• CuLA effectively induced mitochondrial dysfunction and apoptosis in SKOV-3 cells.
• CuLA suppressed cyclooxygenase-2 expression in RAW 264.7 cells, indicating anti-inflammatory effects.
• The analogue complex CuL showed lower cytotoxic activity and lacked significant anti-inflammatory effects.
• CuLA demonstrated dual anticancer pathways involving DNA damage and mitochondrial dysfunction.

Conclusions:

• The copper complex CuLA exhibits significant anticancer and anti-inflammatory activities.
• Incorporation of aspirin ligands enhances the antitumor efficacy and reduces inflammation.
• CuLA represents a novel class of multifunctional metallodrugs with potential for cancer therapy.